CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorVA Office of Research and Development
About this trial
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Eligibility criteria
Qualifiers
On hemodialysis
Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol
Disqualifiers
Impaired decision-making capacity
Patients not receiving carvedilol who have a history of asthma
known hypersensitivity to any component of either drug
Provider unwilling to sign a new medication order for a randomized patient
Trial design
Treatments tested in this trial
- Metoprolol Succinate
- Carvedilol
Treatment groups
2,540 Participants
are divided into 2 treatment groupsLocations
8California
VA Long Beach Healthcare System, Long Beach, CA90822, Long Beach United States
Florida
North Florida/South Georgia Veterans Health System, Gainesville, FL32608-1135, Gainesville United States
Georgia
Atlanta VA Medical and Rehab Center, Decatur, GA30033-4004, Decatur United States
Iowa
Iowa City VA Health Care System, Iowa City, IA52246-2292, Iowa City United States
Sponsors and collaborators
VA Office of Research and Development
Lead sponsor
Source ClinicalTrials.gov